Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis

International Journal of Cancer

Volumn 133, Issue 6, 2013, Pages 1334-1344

  Franses, Joseph W ^a   Drosu, Natalia C ^a   Gibson, William J ^a   Chitalia, Vipul C ^b   Edelman, Elazer R ^a,c  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

angiogenesis; endothelium; inflammation; metastasis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL FUNCTION; CELL STIMULATION; CELL SURVIVAL; CELLULAR SECRETION; CYTOKINE RELEASE; DYSFUNCTIONAL ENDOTHELIUM CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LEWIS CARCINOMA; METASTASIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; VASCULAR SURGERY;

ANGIOGENESIS; ENDOTHELIUM; INFLAMMATION; METASTASIS;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 84879892308     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28146     Document Type: Article

References (50)

1. Michiels C,. Endothelial cell functions. J Cell Physiol 2003; 196: 430-43.
2. Rogers C, Parikh S, Seifert P, et al. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. Circulation 1996; 94: 2909-14.
3. Nathan A, Nugent MA, Edelman ER,. Tissue engineered perivascular endothelial cell implants regulate vascular injury. Proc Natl Acad Sci USA 1995; 92: 8130-4.
4. Zani BG, Kojima K, Vacanti CA, et al. Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate airway repair. Proc Natl Acad Sci USA 2008; 105: 7046-51.
5. Carmeliet P, Jain RK,. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-27.
6. Franses JW, Baker AB, Chitalia VC, et al. Stromal endothelial cells directly influence cancer progression. Sci Transl Med 2011; 3: 66ra5.
7. Libby P,. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
8. Ingber DE,. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 2002; 91: 877-87.
9. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-90.
10. Bhowmick NA, Neilson EG, Moses HL,. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-7.
11. Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009; 116: 219-30.
12. Bates DO,. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010; 87: 262-71.
13. van Beijnum JR, Dings RP, van der Linden E, et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006; 108: 2339-48.
14. Albini A, Benelli R,. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007; 2: 504-11.
15. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462: 104-7.
16. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
17. Nugent MA, Nugent HM, Iozzo RV, et al. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA 2000; 97: 6722-7.
18. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-61.
19. Potenta S, Zeisberg E, Kalluri R,. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 2008; 99: 1375-9.
20. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117: 3988-4002.
21. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
22. Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997; 272: 21096-103.
23. Methe H, Nugent HM, Groothuis A, et al. Matrix embedding alters the immune response against endothelial cells in vitro and in vivo. Circulation 2005; 112: I89-I95.
24. Butler JM, Kobayashi H, Rafii S,. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010; 10: 138-46.
25. Dodge AB, Lu X, D'Amore PA,. Density-dependent endothelial cell production of an inhibitor of smooth muscle cell growth. J Cell Biochem 1993; 53: 21-31.
26. Nugent MA, Karnovsky MJ, Edelman ER,. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ Res 1993; 73: 1051-60.
27. Ruoslahti E,. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2: 83-90.
28. Castermans K, Griffioen AW,. Tumor blood vessels, a difficult hurdle for infiltrating leukocytes. Biochim Biophys Acta 2007; 1776: 160-74.
29. Houle F, Huot J,. Dysregulation of the endothelial cellular response to oxidative stress in cancer. Mol Carcinog 2006; 45: 362-7.
30. Ghosh K, Thodeti CK, Dudley AC, et al. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc Natl Acad Sci USA 2008; 105: 11305-10.
31. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
32. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
33. Libby P, Ridker PM, Hansson GK,. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
34. Rocha VZ, Libby P,. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 6: 399-409.
35. Erez N, Truitt M, Olson P, et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010; 17: 135-47.
36. Pitroda SP, Zhou T, Sweis RF, et al. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One 2012; 7: e46104.
37. Ashall L, Horton CA, Nelson DE, et al. Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription. Science 2009; 324: 242-6.
38. Ferreiro DU, Komives EA,. Molecular mechanisms of system control of NF-kappaB signaling by IkappaBalpha. Biochemistry 2010; 49: 1560-7.
39. Nugent HM, Groothuis A, Seifert P, et al. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res 2002; 39: 524-33.
40. Bissell MJ, Hines WC,. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320-9.
41. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117: 3846-56.
42. Gilbert LA, Hemann MT,. DNA damage-mediated induction of a chemoresistant niche. Cell 2010; 143: 355-66.
43. Ettenson DS, Koo EW, Januzzi JL, et al. Endothelial heparan sulfate is necessary but not sufficient for control of vascular smooth muscle cell growth. J Cell Physiol 2000; 184: 93-100.
44. Jain RK,. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008; 8: 309-16.
45. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
46. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
47. Folkman J,. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
48. Rak J, Filmus J, Kerbel RS,. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer 1996; 32A: 2438-50.
49. Bandyopadhyay S, Zhan R, Chaudhuri A, et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 2006; 12: 933-8.
50. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.